MSD has pulled back its application to market Keytruda (pembrolizumab) in the European Union in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback